CanJPsychiatry 2012;57 (7): [446][447][448][449][450][451][452][453] Objective: Relative to recent successes in elucidating the genetic mechanisms associated with complex diseases, including macular degeneration, diabetes mellitus, type 2, heart disease, and cancer, molecular genetic approaches to psychiatric illness have met with more limited success. While factors such as small allelic effects, allelic heterogeneity, and variation in population substructure have received considerable attention in attempt to explain the paucity of significant results in psychiatric genetics, significantly less focus has been directed toward phenotypic factors.
Abbreviations
• Studies seeking to assess the relation between genetic variation and the psychosis phenotype may provide insight into the pathophysiological mechanisms of psychiatric illness.
Limitations
• Despite its potential use, there is a very limited amount of work that has been conducted to parse the specific effects of genetic variants on phenotypic factors that are shared among diagnostic groups.
• Large-scale studies using genome-wide association, next-generation sequencing, and other emerging analytic tools targeted at specific phenotypes are needed.
D espite its great use for both research and practice in psychiatry, the conceptual basis of the American Psychiatric Association's DSM remains controversial. The primary basis for this controversy has been the reliance on a categorical approach in which different diagnostic entities share common phenomenological features. This overlap in features associated with diagnostic categories is perhaps most prominent regarding symptoms of psychosis. For example, psychotic phenomena, including positive (that is, hallucinations and delusions), negative (that is, apathy, avolition, and asociality), and disorganized (that is, disorganized speech or behaviour) symptoms, are the cornerstones of SZ; however, as illustrated in Figure 1 , they are often observed across a broad spectrum of diagnoses outside of the nominal psychotic disorders category as defined by the current edition of the DSM. Because psychotic symptoms are not pathognomonic for a specific diagnostic category, classification of a person experiencing these symptoms is based solely on aggregate clinical phenomena. Thus a person who presents with auditory hallucinations and delusional beliefs may be diagnosed with SZ, SAD, BD, or MDD, depending on the presence, course, and severity of concomitant affective symptoms. Owing to the limitations of the categorical approach, it is anticipated that the fifth edition of the DSM, planned for publication in 2013, will include a dimensional approach for key aspects of psychopathology. The examination of such dimensional phenotypes would likely facilitate the identification of some of the molecular genetic mechanisms underlying these complex, syndromal diseases. [1] [2] [3] [4] [5] 
Heritability of Psychosis
Initial support for a dimensional approach to elucidating the molecular genetic mechanisms associated with psychotic symptoms is derived from family studies demonstrating a partial overlap between the psychotic and affective disorders. Specifically, relatives of probands with SZ and BD show some overlap in risk to the alternate disorder as well as an increased rate of both SAD and MDD, relative to control subjects. 6, 7 This overlap is even more pronounced when comparing psychotic affective illness and SZ. For example, the reanalysis of the Iowa 500 sample, using DSM-III criteria, found a significantly increased prevalence of psychotic affective illness in relatives of patients with SZ, compared with control subjects. 8 Similar findings were reported in the Roscommon family sample 9 ; affectively ill relatives of SZ probands were more likely to have psychotic affective illness than relatives of control subjects, and probands with psychotic affective illness were more likely to have relatives with SZ. Similarly, Erlenmeyer-Kimling et al 10 found a significantly elevated prevalence of affective psychoses in the offspring of SZ probands, compared with the offspring of control probands. Finally, Laursen et al 7 demonstrated an increased risk of both BD and SZ in relatives of patients with SAD. Taken together, these epidemiologic data suggest considerable overlap in the heritability of psychiatric illness characterized by the presence of psychosis.
Family-based studies have also demonstrated considerable overlap in the heritability of psychotic symptom dimensions within diagnostic categories. For example, symptom factors, including positive, negative, and affective symptoms, 11 thought withdrawal, thought insertion, thought broadcasting, delusions of control, 12 and disorganization [13] [14] [15] have been found to be significantly correlated in sibling pairs (including twins) concordant for psychotic illness. Moreover, a meta-analysis of family-based studies of BD demonstrated statistically significant familial aggregation for the psychosis phenotype. 5 Finally, subthreshold psychotic symptoms, such as paranoid ideation, altered perceptual experiences, odd or magical thinking, and social isolation, are often observed in unaffected relatives of people with psychotic illness, with family-based studies consistently indicating a moderate heritability of psychosis-related phenotypes even when diagnostic status is discordant. 16 The convergence of these findings provides strong support for the notion that the psychosis dimension has a heritable component.
Despite the convincing evidence suggesting familial aggregation and heritability of psychosis phenotypes, relatively limited work has been conducted to identify the molecular underpinnings of this shared familial risk. In fact, most research in psychiatric genetics has been predicated on the assumption that psychiatric diagnoses are distinct disease entities with distinct etiologies. However, the overlap in diagnostic categories containing features of psychosis suggests that psychiatric diagnoses are not distinct disease entities. Therefore, it is not surprising that considerable overlap in the molecular mechanisms associated with psychiatric disorders, particularly among the psychotic and affective disorders, has been repeatedly supported by linkage studies, 5 candidate gene studies, 17 and, more recently, by GWASs. 18
Evidence Derived From Genetic Linkage Studies
The linkage evidence in support of shared genetic risk factors for psychosis comes primarily from linkage studies of BD and SZ. Initial evidence for overlap in the genetics of these disorders came from a large meta-analysis of SZ and BD that indicated strong combined linkage evidence at several loci, including 1p13.
, and 22pter-q12.3. 19 Based on independent findings from multiple studies in both disorders, other chromosomal regions, including 1q42, 6q22, and 15q14, have also been shown to overlap in SZ and BD. 20 Follow-up studies testing the hypothesis that BD pedigrees enriched for psychotic symptoms would show increased evidence of linkage to chromosomal regions of prior overlap between BD and SZ demonstrated that there were at least 4 overlapping chromosomal regions that could harbour shared susceptibility genes. These included regions on 13q31, 22q12, 10p12-14, and 18p11.2. 6 The psychotic BD subtype was further studied in a genome-wide linkage analysis of 40 extended BD pedigrees with psychotic features; significant evidence was reported for linkage at 9q31 and 8p21, with suggestive evidence at 13q32, all of which had been previously implicated in SZ. 21 Further, it should be noted that the region on chromosome 13q has also been linked to MDD. 22 Unfortunately, of the few linkage studies that have been conducted on extended MDD pedigrees, none have focused on the psychosis phenotype within the broader diagnostic category. Finally, Fanous et al 23 used a genome scan correlation method to test for a genetic correlation between SZ and schizotypy. The results of these analyses suggested that a subset of SZ susceptibility genes also affects schizotypy in nonpsychotic relatives. 
Evidence Derived From Candidate Gene Studies
Consistent with the aforementioned linkage evidence, data from candidate gene studies also suggest considerable overlap in genetic susceptibility across diagnostic categories 17 and implicate several well-known candidate genes, including: DTNBP1, DISC1, NRG1, DAOA, COMT, G-protein signalling 4 (RGS4), and others in shared risk for the psychotic illnesses across traditional DSM boundaries. Moreover, several of these candidate genes have now been linked to specific clinical profiles within, and in some cases across, diagnostic categories.
The DAOA (G72/G30) Gene
Chumakov et al 24 first reported associations between SZ and markers in DAOA (previously known as G72 and G30), overlapping genes transcribed in opposite directions on chromosome 13q34, in a relatively large European cohort. Associations to SZ in this region are supported by at least 2 meta-analyses, 25, 26 although there is no consensus concerning the specific risk alleles or haplotypes across studies. Schumacher et al 27 reported an overlap in the association between SNPs within DAOA and risk for both SZ and BD. Specifically, these authors assessed a sample of 599 patients (299 with SZ, 300 with BD) and 300 control subjects, and reported an association between SZ and several SNPs in a 4-marker haplotype, with the most significant SNP, as well as the haplotype, also showing nominal association to BD. Follow-up studies of DAOA have consistently replicated the association between DAOA and BD, and it is now considered one of the best supported candidate gene loci for BD. 17 Finally, Rietschel et al 28 assessed the relation between DAOA and MDD in 500 patients and 1030 population-based control subjects and reported a significant association at the same haplotype identified by Schumacher et al. 27 The convergence of these data suggest that variation at DAOA may be more closely linked to specific aspects of psychiatric illness that cross the diagnostic boundaries of the DSM-IV than to a specific diagnostic category.
Data also suggests that DAOA may be associated with specific phenotypes of psychiatric illness rather than a specific diagnostic group. Specifically, Schulze et al 29 found that persecutory delusions were the only significant explanatory variable for a previously identified risk genotype shared in SZ and BD. Moreover, in a study of SZ and BD, Williams et al 30 found that variation at DAOA was more significantly associated with major mood episodes across these disorders rather than categorical diagnoses. Finally, Corvin et al 31 assessed the relation between a previously identified risk variant in DAOA and symptom factors derived from the Positive and Negative Syndrome Scale (commonly referred to as PANSS) in a sample of patients with SZ and SAD. These authors found that carriers of the DAOA risk variant scored significantly higher on a depression and anxiety factor than noncarriers (P = 0.01). Again, these data suggest that DAOA may influence phenotypic variation that traverses the traditional DSM-IV categories.
The NRG1 Gene.
NRG1 was first implicated in SZ after a systematic study of 8p21-22 revealed an association between a haplotype at the 5′ end of NRG1 and SZ. 32 Additional support for this association was later provided by findings in 2 separate case-control samples. 33, 34 Moreover, a review of the NRG1 literature 35 concluded that despite some differences in the associated haplotypes, the evidence for an association between NRG1 and SZ is quite strong. Although NRG1 has not yet been extensively studied in BD, a few studies 36, 37 found significant evidence for an association between an SZ risk haplotype within NRG1 and BD. Moreover, in the Green et al 36 study the strength of the association was substantially increased in BD patients with predominantly mood-incongruent psychotic features, and SZ patients who had experienced mania. Goes et al 38 also reported findings suggesting that NRG1 may be specifically associated with the psychotic subset of BD probands. Thus these data suggest that NRG1 may play a role in susceptibility to both SZ and BD, and further suggest that it may exert a specific effect on phenotypic variation that crosses diagnostic boundaries. Families, several SNPs within DTNBP1, alone or in combination, increased the risk for SZ. To date, several replication studies in different populations of European descent have been reported, and a comprehensive metaanalysis suggests that DTNBP1 is one of the most robust association signals in the literature. 40 Although the data linking DTNBP1 variation to BD are limited, Raybould et al 41 found modestly significant evidence for association in a subset of patients with BD and predominantly psychotic episodes. Moreover, Domschke et al 42 recently found modest evidence for an association between variants in DTNBP1 and psychotic MDD. Collectively, these findings suggests that variation in DTNBP1 may confer risk to the psychotic syndrome rather than a specific DSM-IV diagnosis.
The DTNBP1 Gene
Available data also suggest that DTNBP1 may be more closely related to a dimension of negative symptoms than a specific diagnostic category. Negative symptoms are a particularly attractive phenotype for genetic investigation, as they tend to be more stable across the duration of illness, may present prior to the onset of illness, and are often unaffected by antipsychotic drug treatment. 43 Moreover, heritability studies of clinical symptomatology have indicated that affected relative pairs with SZ may share similar severity of negative symptoms more often than expected by chance, 11 indicating a substantial genetic component. Data from several groups suggest that negative symptoms may be influenced by DTNBP1 genotype. For example, Fanous et al 44 assessed 755 subjects with psychotic illness in the Irish Study of High Density Schizophrenia Families with the OPCRIT, 45 with factor analyses revealing that an 8-marker SZ risk haplotype was overtransmitted to subjects with greater negative symptom factor scores. These findings have been replicated by multiple groups using measures of negative symptoms, including lifetime severity, 46, 47 longitudinal course, 48 and cross-sectional severity. [49] [50] [51] Taken together, these independent studies suggest that DTNBP1 variants may influence negative symptom dimensions rather than a specific diagnostic category.
The DISC1 Gene
The gene encoding DISC1 is located at the break point of a balanced translocation between chromosomes 1 and 11, (1;11)(q42;q14), that was originally identified in an extended psychiatric pedigree and was shown to co-segregate with multiple major psychiatric disorders, including SZ, SAD, BD, and MDD. 52, 53 Genome scans [53] [54] [55] and candidate gene analyses 56, 57 have consistently linked DISC1 with risk for several psychiatric disorders, including a report of multiple haplotypes within DISC1 associated with both affective and psychotic disorders. 58 The considerable overlap in findings relating DISC1 to a broad spectrum of affective and psychotic disorders suggests that variation in DISC1 may confer risks that traverse diagnostic boundaries.
Initial support for the relation between variation in DISC1 and specific clinical profiles was provided by Hennah et al. 56 These researchers assessed 458 Finnish SZ families and identified a single common, undertransmitted haplotype (HEP3) that significantly increased risk for the development of SZ. However, additional analyses using more refined phenotypes that included factor scores derived from the OPCRIT indicated that the risk haplotype was more significantly associated with a specific clinical profile characterized by high loading on factor scores that included delusions and hallucinations, manic symptoms, depressive symptoms, and negative symptoms. The strongest of these findings indicated association of DISC1 HEP3 to the delusions and hallucination factor, and, within this factor, the strongest association to HEP 3 was persecutory delusions (P < 0.001). Follow-up work in at least one additional patient sample has replicated these results, suggesting that a known DISC1 SZ risk haplotype is more closely linked to lifetime measure of delusions. 59 However, perhaps more convincing is the finding that DISC1 may associate to dimensions of psychosis in a general population sample. Specifically, Tomppo et al 60 found that in a large, unselected birth cohort, variation at DISC1 was strongly associated with social anhedonia, a cardinal symptom of SZ. Collectively, these data suggest that DISC1 risk genotypes may be more closely related to dimensions of psychosis rather than a specific diagnostic category.
The COMT Gene
COMT is an enzyme involved in the degradation of the neurotransmitter dopamine and has received considerable attention in molecular genetic studies of psychiatric populations. The gene encoding COMT is located in the region on chromosome 22q11, commonly deleted in the VCFS, or the Di George, syndrome, whose phenotypic spectrum includes severe psychiatric disease that has been described as both SZ and BD. 61 To date, a plethora of candidate gene studies have found evidence for a link between variation in COMT and psychiatric illness, and, in contrast to other candidate gene studies, the SNPs and haplotypes implicated in the different diseases are strikingly similar. For example, Shifman et al 62, 63 identified a single haplotype within COMT that increased risk for both SZ 62 and BD. 63 These data suggest that it is likely that the association between COMT genotype and psychiatric illness may be better characterized by assessing the effect of COMT genetic variation on the overlapping clinical profiles of psychiatric illness.
To date, much of the work relating variation in COMT to symptom dimensions within psychiatric samples has focused on its relation to affective symptoms. [64] [65] [66] However, data derived from nonclinical samples suggest that variation at COMT may be associated with dimensions of psychosis. Stefanis et al 67 first reported an association of the Val158Met allele of COMT to measures of schizotypy in a sample of 543 males derived from a nonclinical population. These authors reported a significant effect of the high-activity valine allele load on negative and disorganized dimensions of schizotypy as measured by the Schizotypal Personality Questionnaire. 68 These data have been replicated by the same group in a much larger sample comprised of 2130 young males 69 as well as independent samples. 70, 71 Moreover, van Winkel et al 72 recently tested for an association between variants of COMT and psychosis as measured by the BPRS in unaffected relatives of patients with SZ. These authors reported that sharing of the methionine allele of COMT between affected and unaffected relative pairs was a significant predictor of an association between the affected and unaffected relative pairs' scores on the BPRS. These data suggest that genetic variation may be, at least in populations with a genetic predisposition to psychosis, related to the pathophysiology of psychosis.
Other Candidate Genes
The evidence reviewed above suggests that delineation of the role of specific genes on symptom dimensions, rather than diagnostic entities, may lead to more refined approaches and may suggest novel treatment targets for specific domains of illness. It should also be noted that in addition to the overlapping effects of the aforementioned risk genotypes, many studies have also demonstrated associations between symptom domains and variants within genes not associated with diagnostic categories. These include relations between negative symptoms and brain-derived neurotrophic factor (BDNF 73 ), dicarboxylate-amino acid cation sodium transporter (DAT1 73 ), and heterotetrameric potassium channel (hKCa3 74 ); positive symptoms and dopamine receptor genes (DRD4 75 and DRD2 76 ), a cholecystokinin analogue (CCK-A 77 ), and a functional serotonin transporter (5-HTT 78 ); and disorganization with DRD2. 76 Thus specific genetic variants may act to modify 79 the clinical presentation of illness without increasing the risk for the illness.
Evidence Derived From Linkage Using Quantitative Traits for Symptom Dimensions
An alternative approach to candidate gene studies is the use of genetic linkage approaches that have the capacity to detect novel loci located within relatively large chromosomal regions. To date, a very limited number of studies have used this approach. However, results of these studies have identified several regions on chromosomes 6, 80,81 8, 81,82 9, 12, 81 and 20, 23,81 that are associated with dimensions of psychosis in SZ, suggesting that several regions of the genome may harbour genes that influence the clinical features rather than diagnosis. Although some of the regions suggestive of linkage to these quantitative traits, including several loci on chromosomes 6 and 8, had previously been linked to SZ, the regions identified on chromosomes 9, 12, and 20 had not been previously linked to the disease. Thus these data suggest that these regions on the genome may harbour genes that influence the clinical features of SZ without increasing the risk for the illness, and followup analyses have supported these findings. Specifically, our group (see DeRosse et al 83 ) identified an association between positive psychotic symptoms in patients with SZ and an SNP in the gene encoding for the origin recognition complex 3L (ORC3L) located within the linkage regions previously associated with positive symptoms. 80 Moreover, we also identified and association between disorganization in patients with SZ and several SNPs in the gene encoding for brain-specific angiogenesis inhibitor 3 (BAI3) located within the linkage region previously associated with disorganization. 81 Although preliminary, these data point toward specific candidate genes located within previously implicated linkage peaks for psychotic symptoms and provide additional support for the role of genetic variation in dimensional measures of psychosis.
Summary and Future Directions
Accumulating evidence supports the role of genetic factors in variation across the psychosis phenotype and may suggest an overlap in the pathophysiological mechanisms of psychotic illness. Such findings challenge the current concepts of disease classification and demonstrate the potential use of a symptom-based, dimensional approach. Data derived from large-scale, collaborative GWASs in psychiatry, albeit quite limited, provide strong support for such an approach. Indeed, many of the genetic variants that have been identified in GWASs support what had previously been observed, both in linkage and in candidate gene studies; they suggest considerable overlap between diagnostic categories. For example, Williams et al 84 recently reported that of the 8 robust associations that have been identified in GWASs for SZ or BD, 6 of them show strong trans-disorder effects. Indeed, the largest psychiatric GWASs to date 85 recently reported that when SZ and BD are analyzed jointly, the number of genome-wide significant loci increases with an enhancement of signals at loci previously shown to confer risk to both disorders. These data are consistent with data derived from the International Schizophrenia Consortium, which showed that common polygenic variation explained about one-third of the variation in liability to SZ, and the same polygenic variation was substantially shared with BD. 86 Follow-up analyses using the same polygenic model in an independent sample demonstrated that the observed overlap may relate more closely to the sharing of an SZ-like phenotype. 87 Given the clinical heterogeneity and molecular complexity of psychiatric illness, it is unlikely that any single genetic paradigm will account for a large degree of the variance to be explained. However, the exploration of relations between genetic variation and symptom variation that traverses traditional diagnostic boundaries may ultimately lead to more refined classification systems that more closely reflect the genetic etiology of psychiatric illness.
